GlassScriptPhysician profile
Ritoo Gagneja
NPI 1093966236
$14,103.19
in general payments reported to CMS, 2019-2025
61 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $1,921 · 2021: $1,987 · 2022: $2,338 · 2023: $2,045 · 2024: $2,120 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,466.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,521.70 | 2019-2025 | |
| Amgen INC. | $1,460.04 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,264.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,256.03 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $1,018.44 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $844.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $827.67 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $723.19 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $586.50 | 2019-2025 | |
| Astellas Pharma US INC | $483.47 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $436.66 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $436.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $389.83 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Allergan, INC. | $329.31 | 2020-2021 | |
| Amarin Pharma, INC. | $249.97 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritoo Gagneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.